Loren Data's SAM Daily™

fbodaily.com
Home Today's SAM Search Archives Numbered Notes CBD Archives Subscribe
SAMDAILY.US - ISSUE OF DECEMBER 12, 2019 SAM #6587
SOLICITATION NOTICE

65 -- Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program

Notice Date
12/10/2019 10:33:48 AM
 
Notice Type
Solicitation
 
NAICS
325412 — Pharmaceutical Preparation Manufacturing
 
Contracting Office
DEFENSE HEALTH AGENCY - AURORA AURORA CO 80011 USA
 
ZIP Code
80011
 
Solicitation Number
HT9402-20-Q-0001(2)
 
Response Due
12/31/2019 10:00:00 AM
 
Archive Date
06/01/2020
 
Point of Contact
Yvette Dluhos
 
E-Mail Address
yvette.h.dluhos.civ@mail.mil
(yvette.h.dluhos.civ@mail.mil)
 
Description
Background:The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.P&T COMMITTEE MEETING: February 2020: The following drug classes/subclass and newly approved agents will be reviewed:Acne Agents, SUB CLASS: Topical Acne and Rosacea - AmzeeqOncological Agents, SUB CLASS: N/A - BrukinsaKeratolytics, SUB CLASS: N/A - EnzoclearHematological Agents, SUB CLASS: Sickle Cell Anemia Agents - OxybrytaAntitubercular Agents, SUB CLASS: N/A - PretomanidHematological Agents, SUB CLASS: White Blood Cell Stimulants - ZiextenzoRFQ: The RFQ, including UF BPA and UF ADP appendices are attached herein. Pre-proposal teleconference is on December 18, 2019, details are stated in Part 2.5. Clinical Questions in Part 3.4 shall be submitted via e-mail to the RFQ Point of Contact stated in Part 2.3, no later than the date stated in Part 2.4.
 
Web Link
SAM.gov Permalink
(https://beta.sam.gov/opp/71647d4a70cf4e5a92c3730304bd1fc0/view)
 
Place of Performance
Address: 65000, TX 78230, USA
Zip Code: 78230
Country: USA
 
Record
SN05513334-F 20191212/191210230254 (samdaily.us)
 
Source
SAM.gov Link to This Notice
(may not be valid after Archive Date)

FSG Index  |  This Issue's Index  |  Today's SAM Daily Index Page |
ECGrid: EDI VAN Interconnect ECGridOS: EDI Web Services Interconnect API Government Data Publications CBDDisk Subscribers
 Privacy Policy  Jenny in Wanderland!  © 1994-2024, Loren Data Corp.